Strong Earnings Boost for Apollo Hospitals

The healthcare giant, Apollo Hospitals Enterprises, has made quite a splash with its latest financial report, showcasing a remarkable 83% surge in its consolidated profit after tax. For the first quarter of FY25, the profits soared to ₹305 crore, a substantial increase from ₹167 crore during the same period last year. This impressive growth can be attributed to a robust rise in revenues across the board.

Impressive Growth in Earnings Before Tax

Furthermore, the company reported a 33% increase in its consolidated EBITDA, reaching ₹675 crore compared to last year’s ₹509 crore, signifying healthy financial activity.

Revenue From All Corners

Consolidated revenue from operations showed a commendable growth of 15%, hitting ₹5,086 crore as opposed to ₹4,418 crore in the previous year. This uptick was fueled by contributions from all segments within the organization.

Specifically, the revenues for healthcare services, AHLL (Apollo Health and Lifestyle Ltd), and Apollo HealthCo—the latter which encompasses pharmacy distribution and digital health—each grew by 15% as well, with figures arriving at ₹2,637 crore, ₹366 crore, and ₹2,082 crore respectively. Despite these gains, both AHLL and Apollo HealthCo faced operational losses, while the healthcare services segment remained profitable.

Bed Occupancy and Patient Growth

As of June 30, 2024, Apollo Hospitals boasts a network of 7,942 operational beds (excluding AHLL and managed beds). The hospital occupancy rate stood at 68%, an improvement from 62% last year, driven by a significant uptick in patient visits. Inpatient volume grew by 11% and outpatient new registrations saw a rise of 13%. Notably, the average revenue per inpatient reached ₹158,250, a growth of 3%.

Segment Revenue Highlights

In terms of finances, inpatient revenue also painted a positive picture, amounting to ₹2,328 crore for Q1 FY25—up from ₹2,033 crore, marking a 14.5% increase. The contributions from various specializations were significant as well: 19% from cardio, 17% from oncology (including radiotherapy and chemotherapy), and 10% each from neuro and orthopedics. Outpatient revenue was recorded at ₹571 crore, up from ₹504 crore.

Optimism Ahead

“In the first quarter of FY25, we have seen significant growth and improved the reach of our retail operations,” stated Prathap C. Reddy, Chairman of Apollo Hospitals Group, reflecting on the company’s positive trajectory.

Stock Performance

On the Bombay Stock Exchange, the company’s shares closed at ₹6,586.55 apiece, marking a 1.2% increase on Tuesday—a reflection of confidence from investors in these promising results.